Randomized Study Comparing Radiofrequency Ablation with the PVAC Gold System vs. Antiarrhythmic Drugs in Elderly Patients with Symptomatic Atrial Fibrillation

• Published in: Arquivos brasileiros de cardiologia Vol. 121; no. 6; p. e20230684
• Main Authors: Martins, Luiz Claudio Berhmann, Pisani, Cristiano F, Dorfman, Fabio K, Darrieux, Francisco C C, Wu, Tan C, Ferraz, Alberto P, Hachul, Denise T, Castro, Claudio Campi de, Prado, Rogério Ruscitto do, Souza, Luciana V F, Sacilloto, Luciana, Pessente, Gabrielle D A, Grupi, Cesar J, Chokr, Muhieddine Omar, Nomura, Cesar H, Oliveira, Kátia Rodrigues de, Balbo, Conrado P, Melo, Sissy L, Veronese, Pedro, Scanavacca, Mauricio I
• Format: Journal Article
• Language: English; Portuguese
• Published: Brazil 01.06.2024
• Subjects: Aged; Amiodarone - therapeutic use; Anti-Arrhythmia Agents - therapeutic use; Atrial Fibrillation - drug therapy; Atrial Fibrillation - physiopathology; Atrial Fibrillation - surgery; Atrial Fibrillation - therapy; Catheter Ablation - methods; Female; Humans; Male; Pulmonary Veins - surgery; Quality of Life; Recurrence; Time Factors; Treatment Outcome
• ISSN: 0066-782X; 1678-4170
• DOI: 10.36660/abc.20230684i

There are no randomized studies comparing the maintenance of sinus rhythm after catheter ablation (CA) concerning treatment with antiarrhythmic drugs (AA) in elderly patients with paroxysmal atrial fibrillation (AF). To compare the clinical results of pulmonary vein (PV) isolation with the second-generation PVAC Gold catheter against AA treatment in elderly people with recurrent symptomatic paroxysmal AF, refractory to at least one AA, and without structural heart disease. Sixty patients with paroxysmal AF ≥ 65 years old were randomized to two forms of treatment: group 1: CA and group 2: AA drugs. The primary outcome was the AF recurrence-free rate after at least one year of follow-up. Secondary outcomes were: progression to persistent forms of AF, impact on quality of life (QOLF), and complications. The significance level adopted in the statistical analysis was 5% (p<0.05). The AF recurrence-free rate was 80% (10% with amiodarone) in the CA group, after 1.3 procedures per patient and 65% in the AA group (60% with amiodarone), (p = 0.119) in an average follow-up of 719 days (Q1: 566; Q3: 730). The persistent AF free rate was 83.4% in the AC group and 67.7% in the AA group (p = 0.073) Both strategies showed an improvement in the AFQoL score during follow-up (p < 0.001), with no difference between the groups. Although without clinical repercussions or impact on the intellectual assessment test, 25% of patients in the CA group showed signs of cerebral embolization on brain MRI. Both strategies for maintaining sinus rhythm promoted an improvement in the quality of life of elderly patients with symptomatic AF, with no statistical difference in the clinical outcomes. Additional studies using technologies with a better safety profile are needed to evaluate the benefits of CA in elderly patients with AF.